The Institute for Research in Biomedicine, Vall d’Hebron Institute of Oncology, Josep Carreras Leukaemia Research Institute, Sant Joan de Déu…
Selected as an Oral Presentation during the American Society of Clinical Oncology (ASCO) 2021 Virtual Annual Meeting, 04 – 08…
Selected by the American Society of Clinical Oncology (ASCO) as an Oral Presentation during its 2021 Virtual Annual Meeting,…
Full results from the OlympiA Phase III, multicenter trial promise to extend the use of PARPi olaparib as adjuvant therapy…
Barcelona, May 25, 2021- Results from a survey published today in the European Society for Medical Oncology’s (ESMO) open access journal,…
Barcelona, May 12, 2021- Cervical cancer is the fourth most frequently diagnosed cancer and the fourth leading cause of cancer death…
2020 was a year of darkness as the COVID-19 pandemic wreaked its havoc globally. In its waves, it ravaged human…
Ability Pharmaceuticals Announces the Inclusion of the First Patients in a Phase 2b Clinical Trial with ABTL0812 + FOLFIRINOX as…
Launched back in 2019, our VHIO – CaixaResearch Scientific Seminars Series welcomes internationally renowned researchers and clinical investigators to VHIO to share, discuss…
Supported by the preliminary results* reported from the multi-center, phase I GARNET ongoing study — showing the promise of a…
A study in which the VHIO has participated would seem to show that the combination of durvalumab, an anti-PD-L1 monoclonal…
Commonly used liquid biopsy techniques test for tumour mutations in a single gene or in a specific set of genes…
